News - Response Genetics Inc.
SAN FRANCISCO, July 31 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI) today announced the execution of a letter of intent (LOI) to collaborate with Response Genetics, Inc. (Nasdaq: RGDX) on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues.
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce third quarter 2008 financial results Friday, November 7 after close of market.
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sales of molecular diagnostic tests for cancer, today announced that its management will present at the Maxim Group Growth Conference in New York on Oct. 7. The conference will be held at the Grand Hyatt New York Hotel.
FORT MYERS, Fla., Sept. 29 /PRNewswire-FirstCall/ -- NeoGenomics Laboratories (BULLETIN BOARD: NGNM) , a national clinical reference laboratory specializing in high-complexity, cancer-specific testing, announced today an exclusive agreement with Response Genetics Inc.